Home LiteratureArticle Details
PMID: 24132290 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Mutational landscape and significance across 12 major cancer types.

Nature ·Vol. 502 ·No. 7471 ·2013-10-17 ·Pages 333-339

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L

Abstract

The Cancer Genome Atlas (TCGA) has used the latest sequencing and analysis methods to identify somatic variants across thousands of tumours. Here we present data and analytical results for point mutations and small insertions/deletions from 3,281 tumours across 12 tumour types as part of the TCGA Pan-Cancer effort. We illustrate the distributions of mutation frequencies, types and contexts across tumour types, and establish their links to tissues of origin, environmental/carcinogen influences, and DNA repair defects. Using the integrated data sets, we identified 127 significantly mutated genes from well-known (for example, mitogen-activated protein kinase, phosphatidylinositol-3-OH kinase, Wnt/β-catenin and receptor tyrosine kinase signalling pathways, and cell cycle control) and emerging (for example, histone, histone modification, splicing, metabolism and proteolysis) cellular processes in cancer. The average number of mutations in these significantly mutated genes varies across tumour types; most tumours have two to six, indicating that the number of driver mutations required during oncogenesis is relatively small. Mutations in transcriptional factors/regulators show tissue specificity, whereas histone modifiers are often mutated across several cancer types. Clinical association analysis identifies genes having a significant effect on survival, and investigations of mutations with respect to clonal/subclonal architecture delineate their temporal orders during tumorigenesis. Taken together, these results lay the groundwork for developing new diagnostics and individualizing cancer treatment.

MeSH Terms
Carcinogenesis/genetics Cell Cycle/genetics Clone Cells/metabolism,pathology Cohort Studies DNA Repair/genetics Humans INDEL Mutation/genetics Mitogen-Activated Protein Kinases/genetics Models, Genetic Mutation/genetics Neoplasms/classification,genetics,metabolism,pathology Oncogenes/genetics Phosphatidylinositol 3-Kinases/genetics Point Mutation/genetics Receptor Protein-Tyrosine Kinases/metabolism Survival Analysis Time Factors
Chemicals
Phosphatidylinositol 3-Kinases Receptor Protein-Tyrosine Kinases Mitogen-Activated Protein Kinases
Authors & Affiliations
19 authors, click to expand affiliations / ORCID
Kandoth Cyriac
The Genome Institute, Washington University in St Louis, Missouri 63108, USA.
McLellan Michael D
The Genome Institute, Washington University in St Louis, Missouri 63108, USA.
Vandin Fabio
Department of Computer Science, Brown University, Providence, Rhode Island 02912, USA.
Ye Kai
The Genome Institute, Washington University in St Louis, Missouri 63108, USA. | Department of Genetics, Washington University in St Louis, Missouri 63108, USA.
Niu Beifang
The Genome Institute, Washington University in St Louis, Missouri 63108, USA.
Lu Charles
The Genome Institute, Washington University in St Louis, Missouri 63108, USA.
Xie Mingchao
The Genome Institute, Washington University in St Louis, Missouri 63108, USA.
Zhang Qunyuan
The Genome Institute, Washington University in St Louis, Missouri 63108, USA. | Department of Genetics, Washington University in St Louis, Missouri 63108, USA.
McMichael Joshua F
The Genome Institute, Washington University in St Louis, Missouri 63108, USA.
Wyczalkowski Matthew A
The Genome Institute, Washington University in St Louis, Missouri 63108, USA.
Leiserson Mark D M
Department of Computer Science, Brown University, Providence, Rhode Island 02912, USA.
Miller Christopher A
The Genome Institute, Washington University in St Louis, Missouri 63108, USA.
Welch John S
Department of Medicine, Washington University in St Louis, Missouri 63108, USA. | Siteman Cancer Center, Washington University in St Louis, Missouri 63108, USA.
Walter Matthew J
Department of Medicine, Washington University in St Louis, Missouri 63108, USA. | Siteman Cancer Center, Washington University in St Louis, Missouri 63108, USA.
Wendl Michael C
The Genome Institute, Washington University in St Louis, Missouri 63108, USA. | Department of Genetics, Washington University in St Louis, Missouri 63108, USA. | Department of Mathematics, Washington University in St Louis, Missouri 63108, USA.
Ley Timothy J
The Genome Institute, Washington University in St Louis, Missouri 63108, USA. | Department of Genetics, Washington University in St Louis, Missouri 63108, USA. | Department of Medicine, Washington University in St Louis, Missouri 63108, USA. | Siteman Cancer Center, Washington University in St Louis, Missouri 63108, USA.
Wilson Richard K
The Genome Institute, Washington University in St Louis, Missouri 63108, USA. | Department of Genetics, Washington University in St Louis, Missouri 63108, USA. | Siteman Cancer Center, Washington University in St Louis, Missouri 63108, USA.
Raphael Benjamin J
Department of Computer Science, Brown University, Providence, Rhode Island 02912, USA.
Ding Li
The Genome Institute, Washington University in St Louis, Missouri 63108, USA. | Department of Genetics, Washington University in St Louis, Missouri 63108, USA. | Department of Medicine, Washington University in St Louis, Missouri 63108, USA. | Siteman Cancer Center, Washington University in St Louis, Missouri 63108, USA.
References (38)
38 references, click to expand
  1. Bayesian estimation of beta mixture models with variational inference.
    IEEE Trans Pattern Anal Mach Intell. 2011 Nov;33(11):2160-73 PMID: 21422484
  2. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.
    Nat Biotechnol. 2013 Mar;31(3):213-9 PMID: 23396013
  3. The origin and evolution of mutations in acute myeloid leukemia.
    Cell. 2012 Jul 20;150(2):264-78 PMID: 22817890
  4. Cancer genome landscapes.
    Science. 2013 Mar 29;339(6127):1546-58 PMID: 23539594
  5. An integrated genomic analysis of human glioblastoma multiforme.
    Science. 2008 Sep 26;321(5897):1807-12 PMID: 18772396
  6. Comprehensive molecular portraits of human breast tumours.
    Nature. 2012 Oct 4;490(7418):61-70 PMID: 23000897
  7. The consensus coding sequences of human breast and colorectal cancers.
    Science. 2006 Oct 13;314(5797):268-74 PMID: 16959974
  8. De novo discovery of mutated driver pathways in cancer.
    Genome Res. 2012 Feb;22(2):375-85 PMID: 21653252
  9. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
    N Engl J Med. 2013 May 30;368(22):2059-74 PMID: 23634996
  10. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
    Lancet Oncol. 2013 Feb;14(2):159-167 PMID: 23333114
  11. Comprehensive molecular characterization of clear cell renal cell carcinoma.
    Nature. 2013 Jul 4;499(7456):43-9 PMID: 23792563
  12. IDH1 mutation of gliomas with long-term survival analysis.
    Oncol Rep. 2012 Nov;28(5):1639-44 PMID: 22922798
  13. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
    Nature. 2008 Oct 23;455(7216):1061-8 PMID: 18772890
  14. JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data.
    Bioinformatics. 2012 Apr 1;28(7):907-13 PMID: 22285562
  15. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.
    Genome Res. 2012 Mar;22(3):568-76 PMID: 22300766
  16. SomaticSniper: identification of somatic point mutations in whole genome sequencing data.
    Bioinformatics. 2012 Feb 1;28(3):311-7 PMID: 22155872
  17. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
    Nature. 2013 Jul 11;499(7457):214-218 PMID: 23770567
  18. Integrated genomic analyses of ovarian carcinoma.
    Nature. 2011 Jun 29;474(7353):609-15 PMID: 21720365
  19. DNMT3A mutations in acute myeloid leukemia.
    N Engl J Med. 2010 Dec 16;363(25):2424-33 PMID: 21067377
  20. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
    JAMA. 2012 Jan 25;307(4):382-90 PMID: 22274685
  21. DNA methylation in endometrial cancer.
    Epigenetics. 2010 Aug 16;5(6):491-8 PMID: 20543579
  22. DNA methylation in glioblastoma: impact on gene expression and clinical outcome.
    BMC Genomics. 2010 Dec 14;11:701 PMID: 21156036
  23. The biology of chromatin remodeling complexes.
    Annu Rev Biochem. 2009;78:273-304 PMID: 19355820
  24. Somatic mutations affect key pathways in lung adenocarcinoma.
    Nature. 2008 Oct 23;455(7216):1069-75 PMID: 18948947
  25. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    JAMA. 2011 Oct 12;306(14):1557-65 PMID: 21990299
  26. The Pediatric Cancer Genome Project.
    Nat Genet. 2012 May 29;44(6):619-22 PMID: 22641210
  27. Comprehensive molecular characterization of human colon and rectal cancer.
    Nature. 2012 Jul 18;487(7407):330-7 PMID: 22810696
  28. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  29. Whole-genome analysis informs breast cancer response to aromatase inhibition.
    Nature. 2012 Jun 10;486(7403):353-60 PMID: 22722193
  30. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
    Oncotarget. 2012 Jul;3(7):709-22 PMID: 22869205
  31. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
    Nat Genet. 2013 Jan;45(1):18-24 PMID: 23222956
  32. Integrated genomic characterization of endometrial carcinoma.
    Nature. 2013 May 2;497(7447):67-73 PMID: 23636398
  33. MuSiC: identifying mutational significance in cancer genomes.
    Genome Res. 2012 Aug;22(8):1589-98 PMID: 22759861
  34. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
    Science. 2008 Sep 26;321(5897):1801-6 PMID: 18772397
  35. BAP1 loss defines a new class of renal cell carcinoma.
    Nat Genet. 2012 Jun 10;44(7):751-9 PMID: 22683710
  36. The genomic landscapes of human breast and colorectal cancers.
    Science. 2007 Nov 16;318(5853):1108-13 PMID: 17932254
  37. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.
    Nature. 2012 Jan 11;481(7382):506-10 PMID: 22237025
  38. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
    Nature. 2011 Jan 27;469(7331):539-42 PMID: 21248752
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
Published
2013-10-17
Pages
333-339
Language
English
Region
England
NLM ID
0410462
PMCID
PMC3927368
Subset
IM
Grants
NCI NIH HHS · P01CA101937 · United States
NHGRI NIH HHS · R01HG005690 · United States
NHGRI NIH HHS · R01 HG005690 · United States
NHGRI NIH HHS · U54HG003079 · United States
NCI NIH HHS · R01 CA180006 · United States
NHGRI NIH HHS · U01HG006517 · United States
NCI NIH HHS · P01 CA101937 · United States
NHGRI NIH HHS · U54 HG003079 · United States
NCI NIH HHS · R01CA180006 · United States
NHGRI NIH HHS · U01 HG006517 · United States
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com